Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Nanobiotix annonce de nouvelles données précliniques démontrant une amélioration de la biodisponibilité systémique et la réduction de la toxicité pour des immunothérapies à ADN delivrées par LNP après
Regulatory Filings Classification · 48% confidence The document is a corporate press release (“COMMUNIQUÉ DE PRESSE”) announcing new preclinical data for Nanobiotix’s nanoprimer technology presented at a scientific meeting. It is not an investor presentation deck, earnings release, regulatory form, or detailed financial report, nor does it provide formal financial results or governance details. It does not announce a filing or attach a formal report. Therefore it does not fit any specific category and falls into the fallback “Regulatory Filings” category for miscellaneous announcements (RNS).
2026-04-20 French
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Regulatory Filings Classification · 60% confidence The document is a corporate press release announcing new preclinical data and presentation at a scientific conference. It is not an earnings announcement, formal financial report, shareholder voting result, dividend notice, M&A, regulatory/legal filing, nor an investor presentation. It does not qualify under any specific category and serves as a general news announcement. Therefore, it falls into the fallback category for miscellaneous regulatory announcements: RNS.
2026-04-20 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Regulatory Filings Classification · 73% confidence The document is a French-language press release issued under Articles L.233-8 II of the French Commercial Code and AMF regulations providing the monthly update of the total number of shares and voting rights. It is not a full financial report, nor a notice of dividend, nor a threshold crossing or share issue notification; rather, it is a routine regulatory disclosure providing statutory information. This falls into the general "Regulatory Filings" category (Code: RNS) as a miscellaneous mandatory filing that does not fit more narrowly defined categories.
2026-04-07 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release disclosing the company’s number of shares outstanding and total voting rights in accordance with French Commercial Code article L.233-8 II and AMF regulations. It is not a financial report or regulatory filing announcing the publication of a report, but rather an announcement specific to voting rights and share capital. This aligns with the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-04-07 English
DOCUMENT D'ENREGISTREMENT UNIVERSEL 2025
Annual Report (ESEF)
2026-03-31 French
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2025
Annual Report Classification · 95% confidence The document is a detailed press release from Nanobiotix dated March 31, 2026, presenting the company's operational progress and full financial results for the fiscal year 2025. It includes comprehensive financial data such as revenues, R&D expenses, SG&A expenses, net loss, cash position, and financial outlook. It also mentions the filing of the Universal Registration Document (DEU) with the French AMF and the annual report (Form 20-F) with the US SEC for the year ended December 31, 2025. The document contains substantive financial performance information and management commentary on the year's results, which aligns with the characteristics of an Annual Report (10-K equivalent). It is not merely an announcement of a report publication or a brief summary, but a full disclosure of annual financial results and operational highlights. Therefore, the appropriate classification is Annual Report (10-K).
2026-03-31 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.